Top Markets
Coin of the day
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
株式のランク #33997
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
株価
$0.1502
最終同期: 2024-11-04
時価総額
$6.43M
変化(1日)
-5.45%
変化(1年)
0.00%
US
取引 Renalytix Plc (RNLX)

カテゴリー

Renalytix Plc(RNLX)の配当利回りの履歴
Renalytix Plc(銘柄コード: RNLX)の配当利回り(TTM)は2023-06-30時点で0.00%です。
過去5年間の平均配当利回り: 0.00%
Renalytix Plc(RNLX)の2018から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
類似企業または競合他社の配当利回り(TTM)